头孢曲松预防急性脑损伤患者早期呼吸机相关性肺炎:多中心随机双盲安慰剂对照优效性试验
PROPHY-VAP 试验在法国 8 家大学医院 9 个 ICU 纳入需机械通气≥48 小时的昏迷(GCS≤12)急性脑损伤成人患者,随机给予单剂头孢曲松 2 g 或安慰剂。
要点
- 急性脑损伤机械通气患者早期单剂头孢曲松可降低早期 VAP 风险。
- 作者建议将早期单剂头孢曲松纳入此类患者 VAP 预防集束化措施。
核心结论
- 在急性脑损伤需机械通气的患者中,早期单剂头孢曲松可降低早期 VAP 风险,作者建议将其纳入 VAP 预防集束化措施。
研究设计与样本
- PROPHY-VAP 为多中心、随机、双盲、安慰剂对照、评估者设盲的优效性试验,在法国 8 家大学医院 9 个 ICU 开展。
- 纳入 GCS≤12、年龄≥18 岁、急性脑损伤后需机械通气至少 48 小时的成人患者,随机 1:1 分组。
- 插管后 12 小时内静脉给予头孢曲松 2 g 或安慰剂一次,未行选择性口咽及消化道去污染。
- 共随机 345 例(头孢曲松 171 例、安慰剂 174 例),330 例接受分配干预,319 例纳入改良意向治疗分析(头孢曲松 162 例、安慰剂 157 例)。
主要发现
- 分析人群中 166 例(52%)为男性、153 例(48%)为女性。
- 判定确认 93 例 VAP,其中早期感染 74 例。
- 未见微生物学影响,亦无归因于头孢曲松的不良反应。
关键数值与推荐
- 主要结局为机械通气第 2 至第 7 天发生的早期 VAP 比例,由设盲评估者确认。
- 干预为插管后 12 小时内单次静脉头孢曲松 2 g。
临床怎么用
- 对急性脑损伤后需机械通气至少 48 小时的昏迷成人,可考虑插管后 12 小时内单剂头孢曲松 2 g 预防早期 VAP。
- 作者建议将早期单剂头孢曲松纳入此类患者的 VAP 预防集束化措施。
- 实施时需结合本地抗菌药物管理,注意本试验未行选择性口咽及消化道去污染。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with acute brain injury are at high risk of ventilator-associated pneumonia (VAP). The benefit of short-term antibiotic prophylaxis remains debated. We aimed to establish the effect of an early, single dose of the antibiotic ceftriaxone on the incidence of early VAP in patients with severe brain injury who required mechanical ventilation. METHODS: PROPHY-VAP was a multicentre, randomised, double-blind, placebo-controlled, assessor-masked, superiority trial conducted in nine intensive care units in eight French university hospitals. We randomly assigned comatose (Glasgow Coma Scale score [GCS] ≤12) adult patients (age ≥18 years) who required mechanical ventilation for at least 48 h after acute brain injury to receive intravenous ceftriaxone 2 g or placebo once within the 12 h following tracheal intubation. Participants did not receive selective oropharyngeal and digestive tract decontamination. The primary outcome was the proportion of patients developing early VAP from the 2nd to the 7th day of mechanical ventilation, confirmed by masked assessors. The analysis was reported in the modified intention-to-treat population, which comprised all randomly assigned patients except those who withdrew or did not give consent to continue and those who did not receive the allocated treatment because they met a criterion for non-eligibility. The trial is registered with ClinicalTrials.gov, NCT02265406. FINDINGS: From Oct 14, 2015, to May 27, 2020, 345 patients were randomly assigned (1:1) to receive ceftriaxone (n=171) or placebo (n=174); 330 received the allocated intervention and 319 were included in the analysis (162 in the ceftriaxone group and 157 in the placebo group). 166 (52%) participants in the analysis were men and 153 (48%) were women. 15 patients did not receive the allocated intervention after randomisation and 11 withdrew their consent. Adjudication confirmed 93 cases of VAP, including 74 early infections. The incidence of early VAP was lower in the ceftriaxone group than in the placebo group (23 [14%] vs 51 [32%]; hazard ratio 0·60 [95% CI 0·38-0·95], p=0·030), with no microbiological impact and no adverse effects attributable to ceftriaxone. INTERPRETATION: In patients with acute brain injury, a single ceftriaxone dose decreased the risk of early VAP. On the basis of our findings, we recommend that an early, single dose of ceftriaxone be included in all bundles for the prevention of VAP in patients with brain injury who require mechanical ventilation. FUNDING: French Ministry of Social Affairs and Health.
引用
- Dahyot-Fizelier C, Lasocki S, Kerforne T, et al. Ceftriaxone to prevent early ventilator-associated pneumonia in patients with acute brain injury: a multicentre, randomised, double-blind, placebo-controlled, assessor-masked superiority trial. Lancet Respir Med. 2024. PMID: 38262428. doi:10.1016/S2213-2600(23)00471-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。